Maha Abboud, MD
Endocrinology, Diabetes & Metabolism · Melrose Park, ILNPI 1346208956
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $188,929 of the $218,677 with a category attached, or 86.4%. 20 manufacturers reported payments, led by Novo Nordisk at 40.4% of the total. Reporting peaked in 2019 at $105,201 and has fallen 75.9% since, to $25,328 in 2025. Among endocrinology, diabetes & metabolism clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 376 payments — averaging $581.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$88K
- Johnson & Johnson$54K
- Amgen$35K
- Sanofi-aventis U.S. LLC$17K
- Merck$16K
- AstraZeneca$4K
- plus $5K from 14 others
What the payments were for
- Consulting fees$7,9204%
- Speaking & faculty fees$188,92986%
- Travel & lodging$13,4166%
- Food & beverage$8,3204%
- Education$930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 104 | $88,380 |
| Johnson & Johnson | 66 | $54,071 |
| Amgen(2 entities) | 42 | $35,263 |
| Sanofi-aventis U.S. LLC | 17 | $17,026 |
| Merck | 18 | $15,504 |
| AstraZeneca | 7 | $3,622 |
| Abbott | 19 | $2,556 |
| Dexcom, Inc. | 12 | $499 |
| Novartis | 24 | $490 |
| Insulet Corporation | 15 | $476 |
| Corcept Therapeutics | 27 | $327 |
| AbbVie(2 entities) | 7 | $129 |
| Xeris Pharmaceuticals, Inc. | 3 | $63 |
| Sequel Med Tech, LLC | 2 | $61 |
| Lilly USA, LLC | 3 | $55 |
| Tandem Diabetes Care, Inc. | 2 | $50 |
| Amneal Pharmaceuticals LLC | 3 | $45 |
| BETA Bionics, Inc. | 2 | $30 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 2 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVOKANA$53,379
- Ozempic$35,255
- RYBELSUS$32,064
- Prolia$25,952
- TZIELD$16,763
- STEGLATRO$15,402
- Tresiba$9,847
- EVENITY$6,216
- FARXIGA$3,580
- FREESTYLE LIBRE 3$2,205
- DEXCOM G6 TRANSMITTER$252
- FreeStyle Libre$108
How this compares
$218,677 in reported general payments places this provider in the 95th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 175 | $318,872 |
| MounjaroTirzepatide | 110 | $176,679 |
| TrulicityDulaglutide | 53 | $99,371 |
| JardianceEmpagliflozin | 69 | $86,472 |
| FarxigaDapagliflozin Propanediol | 37 | $48,541 |
| JanuviaSitagliptin Phosphate | 38 | $42,466 |
| TradjentaLinagliptin | 31 | $33,962 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 20 | $29,467 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $25,491 |
| ProliaDenosumab | 11 | $19,088 |
| Tresiba Flextouch U-100Insulin Degludec | 28 | $19,011 |
| FiaspInsulin Aspart (Niacinamide) | 11 | $14,187 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 18 | $12,631 |
| SynthroidLevothyroxine Sodium | 61 | $5,817 |
| Repaglinide | 146 | $5,647 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp | $88,380 | $333,059186 claims |
| Lilly USA, LLCMounjaro, Trulicity | $55 | $276,049163 claims |
| AstraZenecaFarxiga | $3,622 | $48,54137 claims |
| MerckJanuvia | $15,504 | $42,46638 claims |
| AmgenProlia | $35,263 | $19,08811 claims |
| AbbVieSynthroid | $129 | $5,81761 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $45 | $5,437447 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Melrose Park
- Terri WashingtonMelrose Park$48K
- Rim JoubranMelrose Park$19K
- Wahid KassarChicago$884K
- Anthony PickLake Forest$665K
- Babak PazookiJoliet$582K
- Ammar BayrakdarEvergreen Park$517K
- George BakrisChicago$403K
- Terrence SwadeLombard$369K
- Wenyu HuangChicago$341K
- Liana BillingsSkokie$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.